Benign Prostatic Hypertrophy Drugs Market by Drug Class (5-Alpha Reductase Inhibitors, Alpha Blockers, Combination Therapy), Generic Status (Branded, Generic), Dosage Form, Distribution Channel - Global Forecast 2025-2032
Description
The Benign Prostatic Hypertrophy Drugs Market was valued at USD 5.50 billion in 2024 and is projected to grow to USD 5.89 billion in 2025, with a CAGR of 7.18%, reaching USD 9.59 billion by 2032.
A strategic orientation to the benign prostatic hypertrophy landscape that delineates clinical drivers, treatment choices, distribution evolution, and commercial imperatives for leaders
The benign prostatic hypertrophy (BPH) therapeutic area stands at a critical inflection point where clinical need, regulatory change, and commercial evolution converge to reshape treatment paradigms. This introduction frames the disease burden, prevailing treatment approaches, and the interplay between originator brands, generics, and alternative therapies. It highlights how physicians and patients are increasingly balancing symptomatic relief, long-term safety, and quality-of-life outcomes when choosing between established pharmacotherapies and emerging adjunctive options.
In the current environment, prescribing behavior is influenced by formulation convenience, adverse-event profiles, and reimbursement dynamics. Meanwhile, distribution channels-from traditional hospital pharmacies to online and retail pharmacies-are transforming how therapies reach patients and how companies engage with payers and prescribers. This section sets the stage for subsequent analysis by outlining the primary clinical and commercial drivers that industry leaders must consider to navigate product lifecycle management, market access strategies, and patient-centered care.
How therapeutic innovation, digital distribution, and evolving patient expectations are jointly reshaping clinical practice and commercial strategies across the benign prostatic hypertrophy market
Transformative shifts in the BPH landscape are being driven by a convergence of therapeutic innovation, evolving patient expectations, and digital-enabled care delivery. Clinical practice is adapting to more nuanced treatment algorithms in which combination therapies and selective alpha blockers play increasingly important roles, and where phytotherapeutic options are receiving renewed attention for patients seeking alternative or adjunctive management strategies. At the same time, extended- and immediate-release formulations across capsules, tablets, and oral solutions are providing new avenues to address adherence and tolerability challenges.
Concurrently, commercialization is being reshaped by the growth of online pharmacy channels, shifts in payer contracting, and the maturation of generics that intensify competitive dynamics. Pharmaceutical companies are responding with lifecycle-extension tactics, selective relabeling, and strategic alliances to protect brand equity. Moreover, advances in real-world evidence generation and telehealth-supported care pathways are enabling more personalized treatment decisions and stronger patient engagement, thereby altering how clinical benefits and value propositions are communicated to stakeholders.
An examination of how tariff adjustments in the United States during 2025 have reshaped supply chain resilience, sourcing strategies, and commercial economics for benign prostatic hypertrophy therapies
The cumulative impact of United States tariffs enacted or adjusted in 2025 reverberates across the BPH pharmaceutical supply chain, influencing sourcing decisions, cost structures, and risk management practices. Raw material and active pharmaceutical ingredient procurement strategies have been reassessed to mitigate exposure to tariff-induced price volatility. Manufacturers and contract suppliers have accelerated diversification of supplier bases, moved to longer-term supply agreements where possible, and explored nearshoring to reduce freight complexity and timing risk.
These tariff dynamics also affect the economics of branded and generic products differently, altering procurement negotiation levers for manufacturers and pharmacies. As a result, companies have revisited pricing strategies, tendering approaches, and inventory policies to maintain supply continuity while protecting margin. At the same time, regulatory scrutiny on import pathways and documentation has increased, prompting firms to strengthen compliance capabilities and invest in supply chain visibility tools that support rapid response to policy shifts. Together, these adaptations are shaping competitive positioning and operational resilience across the BPH therapeutic ecosystem.
In-depth segmentation insights that map therapeutic classes, branded and generic dynamics, distribution channels, and dosage form nuances to commercial and clinical decision-making
Key segmentation insights reveal how distinct therapeutic classes, generic status, distribution channels, and dosage forms create differentiated demand pockets and commercial opportunities. The drug class segmentation spans 5-alpha reductase inhibitors, alpha blockers, combination therapy, and phytotherapy, with the 5-alpha reductase inhibitors further differentiated into dutasteride and finasteride. Alpha blockers are distinguished across multiple agents including alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, while combination therapy is represented by pairings such as dutasteride plus tamsulosin and finasteride plus tamsulosin. Phytotherapy options, including beta-sitosterol, pygeum, and saw palmetto, reflect persistent patient and prescriber interest in plant-derived alternatives and integrative treatment approaches.
Examining generic status reveals distinct commercial pressures between branded offerings-such as Avodart, Flomax, Jalyn, and Proscar-and their off-patent counterparts, with branded recognition often maintaining prescriber preference in specific clinical scenarios while generics drive transactional volume. Distribution channel segmentation highlights the roles of hospital pharmacies, online pharmacies, and retail pharmacies in shaping access, patient experience, and margin structures; each channel imposes unique promotional and logistical requirements. In terms of dosage form, capsules, oral solutions, and tablets are central to product differentiation, with capsule and tablet formulations both available in extended-release and immediate-release variants that influence adherence, tolerability, and prescriber choice. Taken together, these segmentation dimensions inform targeted development plans, channel strategies, and post-market evidence generation efforts.
A regional perspective highlighting how demographic trends, regulatory diversity, and distribution models influence access, adoption, and strategic priorities across global markets
Regional dynamics exhibit nuanced variations driven by demographic trends, regulatory environments, and healthcare infrastructure. In the Americas, aging populations and established primary care referral networks create steady demand for pharmacological management, while payer structures and formulary negotiations exert strong influence over prescribing patterns and access pathways. Manufacturers often prioritize real-world outcomes and health-economic evidence in this region to support coverage decisions and optimize uptake across diverse reimbursement environments.
In Europe, Middle East & Africa, the regulatory mosaic and heterogeneity of public and private payers necessitate differentiated market entry and access strategies. Local clinical guidelines and generics penetration vary substantially, prompting tailored pricing and distribution approaches. In the Asia-Pacific region, a combination of rapidly aging demographics, growing healthcare investment, and expanding retail and online pharmacy ecosystems is accelerating patient access to both established pharmacotherapies and phytotherapeutic alternatives. Across regions, supply chain resilience, regulatory compliance, and culturally informed patient engagement remain critical success factors for companies seeking sustainable presence and growth.
Competitive corporate dynamics and strategic behaviors among originator brands, generic manufacturers, and specialist players that define market positioning and value creation opportunities
Competitive and corporate dynamics among key companies in the BPH space reflect a mix of originator brand stewardship, generics competition, and niche players focused on phytotherapy and specialty formulations. Originator brands continue to leverage clinical familiarity, established safety profiles, and targeted lifecycle strategies to sustain relevance where prescriber preference is strong. Generic manufacturers intensify price competition and broaden channel reach, particularly through partnerships with retail and online pharmacies that prioritize affordability and accessibility.
At the same time, specialist companies and suppliers focused on phytotherapeutic agents and novel delivery systems are carving differentiated niches by aligning product positioning with patient preferences for natural or tolerability-oriented options. Across the competitive spectrum, companies are investing selectively in real-world evidence generation, digital patient support tools, and multi-channel engagement models to support retention and adherence. Strategic collaborations, licensing deals, and selective acquisitions are commonly employed to fill pipeline gaps and extend therapeutic portfolios, reflecting pragmatic approaches to sustaining long-term commercial viability.
Actionable strategic recommendations for industry leaders focused on portfolio optimization, channel alignment, supply chain resilience, and evidence-driven patient engagement to drive sustainable performance
Industry leaders should adopt pragmatic, evidence-driven strategies that balance short-term commercial priorities with long-term portfolio resilience. First, optimizing product portfolios requires aligning formulation choices-extended-release versus immediate-release, capsule versus tablet-with real-world adherence patterns and tolerability profiles, thereby enhancing value propositions to prescribers and payers. Second, companies should prioritize distribution channel strategies that harmonize hospital, retail, and online pharmacy engagement to ensure consistent patient access while addressing margin and promotional constraints.
Moreover, strengthening supply chain resilience through diversified sourcing, strategic inventory management, and enhanced regulatory compliance will mitigate exposure to policy shifts and tariff volatility. Leaders should also invest in targeted real-world evidence programs and digital patient support initiatives that demonstrate comparative effectiveness and drive adherence. Finally, pursuing selective partnerships and lifecycle-extension tactics can protect brand equity while enabling cost-effective entry into new segments, such as phytotherapy or combination therapies, thereby expanding clinical and commercial reach.
A rigorous multi-source research methodology combining secondary evidence, primary stakeholder interviews, and segmentation mapping to ensure robust and actionable insights
The research methodology underpinning the analysis integrates a structured mix of secondary literature review, primary stakeholder engagement, and triangulation of quantitative and qualitative inputs. Secondary research encompassed clinical literature, regulatory guidance, and publicly available product labels to establish therapy characteristics, safety parameters, and formulation differences. Primary research involved interviews with clinicians, payers, distributors, and industry experts to capture practice patterns, access hurdles, and commercial tactics, thereby adding contextual depth to desk-based findings.
Data synthesis employed segmentation mapping across drug class, generic status, distribution channel, and dosage form to ensure insights were aligned to actionable commercial and clinical questions. Quality assurance processes included cross-validation of interview findings against published sources and internal consistency checks to identify and resolve discrepancies. Limitations were acknowledged, including variability in regional data quality and evolving policy landscapes, and where appropriate, the methodology prioritized transparency in assumptions and source provenance to support reproducibility and confidence in strategic conclusions.
A concluding synthesis highlighting the strategic imperatives and integrated approaches needed to navigate clinical demand, competitive pressures, and operational disruptions in the BPH market
In conclusion, the benign prostatic hypertrophy therapeutic arena is characterized by steady clinical demand and intensifying commercial competition shaped by generics, branded lifecycle strategies, and growing interest in phytotherapeutic options. The interplay of formulation innovation, distribution channel evolution, and regulatory and tariff dynamics necessitates agile strategies that align clinical value with operational resilience. Companies that proactively adapt sourcing models, invest in real-world evidence, and finely tune channel engagement will be better positioned to capture durable value while meeting prescriber and patient expectations.
Moving forward, success will hinge on integrating clinical understanding with sophisticated commercial execution-deploying targeted evidence programs, leveraging multi-channel distribution, and applying pragmatic portfolio management. By doing so, stakeholders can navigate near-term disruptions and lay the groundwork for sustained relevance in a market where patient-centered outcomes and cost-effectiveness increasingly define competitive advantage.
Note: PDF & Excel + Online Access - 1 Year
A strategic orientation to the benign prostatic hypertrophy landscape that delineates clinical drivers, treatment choices, distribution evolution, and commercial imperatives for leaders
The benign prostatic hypertrophy (BPH) therapeutic area stands at a critical inflection point where clinical need, regulatory change, and commercial evolution converge to reshape treatment paradigms. This introduction frames the disease burden, prevailing treatment approaches, and the interplay between originator brands, generics, and alternative therapies. It highlights how physicians and patients are increasingly balancing symptomatic relief, long-term safety, and quality-of-life outcomes when choosing between established pharmacotherapies and emerging adjunctive options.
In the current environment, prescribing behavior is influenced by formulation convenience, adverse-event profiles, and reimbursement dynamics. Meanwhile, distribution channels-from traditional hospital pharmacies to online and retail pharmacies-are transforming how therapies reach patients and how companies engage with payers and prescribers. This section sets the stage for subsequent analysis by outlining the primary clinical and commercial drivers that industry leaders must consider to navigate product lifecycle management, market access strategies, and patient-centered care.
How therapeutic innovation, digital distribution, and evolving patient expectations are jointly reshaping clinical practice and commercial strategies across the benign prostatic hypertrophy market
Transformative shifts in the BPH landscape are being driven by a convergence of therapeutic innovation, evolving patient expectations, and digital-enabled care delivery. Clinical practice is adapting to more nuanced treatment algorithms in which combination therapies and selective alpha blockers play increasingly important roles, and where phytotherapeutic options are receiving renewed attention for patients seeking alternative or adjunctive management strategies. At the same time, extended- and immediate-release formulations across capsules, tablets, and oral solutions are providing new avenues to address adherence and tolerability challenges.
Concurrently, commercialization is being reshaped by the growth of online pharmacy channels, shifts in payer contracting, and the maturation of generics that intensify competitive dynamics. Pharmaceutical companies are responding with lifecycle-extension tactics, selective relabeling, and strategic alliances to protect brand equity. Moreover, advances in real-world evidence generation and telehealth-supported care pathways are enabling more personalized treatment decisions and stronger patient engagement, thereby altering how clinical benefits and value propositions are communicated to stakeholders.
An examination of how tariff adjustments in the United States during 2025 have reshaped supply chain resilience, sourcing strategies, and commercial economics for benign prostatic hypertrophy therapies
The cumulative impact of United States tariffs enacted or adjusted in 2025 reverberates across the BPH pharmaceutical supply chain, influencing sourcing decisions, cost structures, and risk management practices. Raw material and active pharmaceutical ingredient procurement strategies have been reassessed to mitigate exposure to tariff-induced price volatility. Manufacturers and contract suppliers have accelerated diversification of supplier bases, moved to longer-term supply agreements where possible, and explored nearshoring to reduce freight complexity and timing risk.
These tariff dynamics also affect the economics of branded and generic products differently, altering procurement negotiation levers for manufacturers and pharmacies. As a result, companies have revisited pricing strategies, tendering approaches, and inventory policies to maintain supply continuity while protecting margin. At the same time, regulatory scrutiny on import pathways and documentation has increased, prompting firms to strengthen compliance capabilities and invest in supply chain visibility tools that support rapid response to policy shifts. Together, these adaptations are shaping competitive positioning and operational resilience across the BPH therapeutic ecosystem.
In-depth segmentation insights that map therapeutic classes, branded and generic dynamics, distribution channels, and dosage form nuances to commercial and clinical decision-making
Key segmentation insights reveal how distinct therapeutic classes, generic status, distribution channels, and dosage forms create differentiated demand pockets and commercial opportunities. The drug class segmentation spans 5-alpha reductase inhibitors, alpha blockers, combination therapy, and phytotherapy, with the 5-alpha reductase inhibitors further differentiated into dutasteride and finasteride. Alpha blockers are distinguished across multiple agents including alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, while combination therapy is represented by pairings such as dutasteride plus tamsulosin and finasteride plus tamsulosin. Phytotherapy options, including beta-sitosterol, pygeum, and saw palmetto, reflect persistent patient and prescriber interest in plant-derived alternatives and integrative treatment approaches.
Examining generic status reveals distinct commercial pressures between branded offerings-such as Avodart, Flomax, Jalyn, and Proscar-and their off-patent counterparts, with branded recognition often maintaining prescriber preference in specific clinical scenarios while generics drive transactional volume. Distribution channel segmentation highlights the roles of hospital pharmacies, online pharmacies, and retail pharmacies in shaping access, patient experience, and margin structures; each channel imposes unique promotional and logistical requirements. In terms of dosage form, capsules, oral solutions, and tablets are central to product differentiation, with capsule and tablet formulations both available in extended-release and immediate-release variants that influence adherence, tolerability, and prescriber choice. Taken together, these segmentation dimensions inform targeted development plans, channel strategies, and post-market evidence generation efforts.
A regional perspective highlighting how demographic trends, regulatory diversity, and distribution models influence access, adoption, and strategic priorities across global markets
Regional dynamics exhibit nuanced variations driven by demographic trends, regulatory environments, and healthcare infrastructure. In the Americas, aging populations and established primary care referral networks create steady demand for pharmacological management, while payer structures and formulary negotiations exert strong influence over prescribing patterns and access pathways. Manufacturers often prioritize real-world outcomes and health-economic evidence in this region to support coverage decisions and optimize uptake across diverse reimbursement environments.
In Europe, Middle East & Africa, the regulatory mosaic and heterogeneity of public and private payers necessitate differentiated market entry and access strategies. Local clinical guidelines and generics penetration vary substantially, prompting tailored pricing and distribution approaches. In the Asia-Pacific region, a combination of rapidly aging demographics, growing healthcare investment, and expanding retail and online pharmacy ecosystems is accelerating patient access to both established pharmacotherapies and phytotherapeutic alternatives. Across regions, supply chain resilience, regulatory compliance, and culturally informed patient engagement remain critical success factors for companies seeking sustainable presence and growth.
Competitive corporate dynamics and strategic behaviors among originator brands, generic manufacturers, and specialist players that define market positioning and value creation opportunities
Competitive and corporate dynamics among key companies in the BPH space reflect a mix of originator brand stewardship, generics competition, and niche players focused on phytotherapy and specialty formulations. Originator brands continue to leverage clinical familiarity, established safety profiles, and targeted lifecycle strategies to sustain relevance where prescriber preference is strong. Generic manufacturers intensify price competition and broaden channel reach, particularly through partnerships with retail and online pharmacies that prioritize affordability and accessibility.
At the same time, specialist companies and suppliers focused on phytotherapeutic agents and novel delivery systems are carving differentiated niches by aligning product positioning with patient preferences for natural or tolerability-oriented options. Across the competitive spectrum, companies are investing selectively in real-world evidence generation, digital patient support tools, and multi-channel engagement models to support retention and adherence. Strategic collaborations, licensing deals, and selective acquisitions are commonly employed to fill pipeline gaps and extend therapeutic portfolios, reflecting pragmatic approaches to sustaining long-term commercial viability.
Actionable strategic recommendations for industry leaders focused on portfolio optimization, channel alignment, supply chain resilience, and evidence-driven patient engagement to drive sustainable performance
Industry leaders should adopt pragmatic, evidence-driven strategies that balance short-term commercial priorities with long-term portfolio resilience. First, optimizing product portfolios requires aligning formulation choices-extended-release versus immediate-release, capsule versus tablet-with real-world adherence patterns and tolerability profiles, thereby enhancing value propositions to prescribers and payers. Second, companies should prioritize distribution channel strategies that harmonize hospital, retail, and online pharmacy engagement to ensure consistent patient access while addressing margin and promotional constraints.
Moreover, strengthening supply chain resilience through diversified sourcing, strategic inventory management, and enhanced regulatory compliance will mitigate exposure to policy shifts and tariff volatility. Leaders should also invest in targeted real-world evidence programs and digital patient support initiatives that demonstrate comparative effectiveness and drive adherence. Finally, pursuing selective partnerships and lifecycle-extension tactics can protect brand equity while enabling cost-effective entry into new segments, such as phytotherapy or combination therapies, thereby expanding clinical and commercial reach.
A rigorous multi-source research methodology combining secondary evidence, primary stakeholder interviews, and segmentation mapping to ensure robust and actionable insights
The research methodology underpinning the analysis integrates a structured mix of secondary literature review, primary stakeholder engagement, and triangulation of quantitative and qualitative inputs. Secondary research encompassed clinical literature, regulatory guidance, and publicly available product labels to establish therapy characteristics, safety parameters, and formulation differences. Primary research involved interviews with clinicians, payers, distributors, and industry experts to capture practice patterns, access hurdles, and commercial tactics, thereby adding contextual depth to desk-based findings.
Data synthesis employed segmentation mapping across drug class, generic status, distribution channel, and dosage form to ensure insights were aligned to actionable commercial and clinical questions. Quality assurance processes included cross-validation of interview findings against published sources and internal consistency checks to identify and resolve discrepancies. Limitations were acknowledged, including variability in regional data quality and evolving policy landscapes, and where appropriate, the methodology prioritized transparency in assumptions and source provenance to support reproducibility and confidence in strategic conclusions.
A concluding synthesis highlighting the strategic imperatives and integrated approaches needed to navigate clinical demand, competitive pressures, and operational disruptions in the BPH market
In conclusion, the benign prostatic hypertrophy therapeutic arena is characterized by steady clinical demand and intensifying commercial competition shaped by generics, branded lifecycle strategies, and growing interest in phytotherapeutic options. The interplay of formulation innovation, distribution channel evolution, and regulatory and tariff dynamics necessitates agile strategies that align clinical value with operational resilience. Companies that proactively adapt sourcing models, invest in real-world evidence, and finely tune channel engagement will be better positioned to capture durable value while meeting prescriber and patient expectations.
Moving forward, success will hinge on integrating clinical understanding with sophisticated commercial execution-deploying targeted evidence programs, leveraging multi-channel distribution, and applying pragmatic portfolio management. By doing so, stakeholders can navigate near-term disruptions and lay the groundwork for sustained relevance in a market where patient-centered outcomes and cost-effectiveness increasingly define competitive advantage.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
186 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of novel β3 agonist therapies targeting bladder smooth muscle relaxation in BPH management
- 5.2. Expansion of digital health platforms integrating telemonitoring and patient reported outcomes in BPH therapy assessment
- 5.3. Emergence of prostate arterial embolization as a minimally invasive alternative to traditional BPH surgical procedures
- 5.4. Development of combination therapy protocols involving 5α reductase inhibitors with phytochemical extracts for enhanced prostate volume reduction
- 5.5. Increasing focus on biomarkers and genetic profiling to personalize benign prostatic hyperplasia pharmacotherapy approaches
- 5.6. Surge in clinical trials evaluating selective androgen receptor modulators to mitigate BPH symptoms with fewer sexual side effects
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Benign Prostatic Hypertrophy Drugs Market, by Drug Class
- 8.1. 5-Alpha Reductase Inhibitors
- 8.1.1. Dutasteride
- 8.1.2. Finasteride
- 8.2. Alpha Blockers
- 8.2.1. Alfuzosin
- 8.2.2. Doxazosin
- 8.2.3. Silodosin
- 8.2.4. Tamsulosin
- 8.2.5. Terazosin
- 8.3. Combination Therapy
- 8.3.1. Dutasteride + Tamsulosin
- 8.3.2. Finasteride + Tamsulosin
- 8.4. Phytotherapy
- 8.4.1. Beta-Sitosterol
- 8.4.2. Pygeum
- 8.4.3. Saw Palmetto
- 9. Benign Prostatic Hypertrophy Drugs Market, by Generic Status
- 9.1. Branded
- 9.1.1. Avodart
- 9.1.2. Flomax
- 9.1.3. Jalyn
- 9.1.4. Proscar
- 9.2. Generic
- 10. Benign Prostatic Hypertrophy Drugs Market, by Dosage Form
- 10.1. Capsule
- 10.1.1. Extended Release
- 10.1.2. Immediate Release
- 10.2. Oral Solution
- 10.3. Tablet
- 10.3.1. Extended Release
- 10.3.2. Immediate Release
- 11. Benign Prostatic Hypertrophy Drugs Market, by Distribution Channel
- 11.1. Hospital Pharmacy
- 11.2. Online Pharmacy
- 11.3. Retail Pharmacy
- 12. Benign Prostatic Hypertrophy Drugs Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Benign Prostatic Hypertrophy Drugs Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Benign Prostatic Hypertrophy Drugs Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. AbbVie Inc
- 15.3.2. Astellas Pharma Inc
- 15.3.3. Bayer AG
- 15.3.4. Boehringer Ingelheim International GmbH
- 15.3.5. Bristol-Myers Squibb Company
- 15.3.6. Eli Lilly and Company
- 15.3.7. Endo Pharmaceuticals Inc
- 15.3.8. GlaxoSmithKline plc
- 15.3.9. Ipsen S.A
- 15.3.10. Johnson & Johnson
- 15.3.11. Kaken Pharmaceutical Co Ltd
- 15.3.12. Kissei Pharmaceutical Co Ltd
- 15.3.13. Merck & Co Inc
- 15.3.14. Novartis AG
- 15.3.15. Pfizer Inc
- 15.3.16. Sanofi S.A
- 15.3.17. Sun Pharmaceutical Industries Ltd
- 15.3.18. Teva Pharmaceutical Industries Ltd
- 15.3.19. Viatris Inc
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
